In the U.S. alone, undiagnosed OSA and non-compliance contribute to a $149 billion annual economic burden.
Besides constant fatigues from lack of sleep, untreated OSA often leads to complications like Type 2 diabetes, heart problems, high blood pressure, and cognitive decay.
Somne will use its patented Variable Negative Pressure technology (vNEP) to provide you with a comfortable alternative to primary OSA treatment.
86% of participants in Somne's IRB-approved human trials prefer Somne's prototype over their primary treatment.
Our goal is to help everyone suffering from OSA as soon as possible.